Skip to content

US · CDNA · MEDICAL - DIAGNOSTICS & RESEARCH

CareDx, Inc (CDNA) intrinsic value and stock valuation

$70.00as of 2026-11-21 · Mkt cap 2.35B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

CareDx, Inc DCF and intrinsic value

InvestorsCraft values CDNA with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from CDNA’s statements →

CareDx, Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Brisbane, CA 94005 caredx.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$379.8M+14.6% 5y CAGRd
20122025
Net income
-$-21.35M
20122025
Free cash flow
$36.1M+9.4% 5y CAGRd
20122025
Total equity
$303.1M+1.8% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$379.8M$333.8M$280.3M$321.8M$296.4M
Operating income-$-25.07M$40.8M-$-203.36M-$-77.23M-$-29.73M
Net income-$-21.35M$52.6M-$-190.28M-$-76.61M-$-30.66M
EPSd-$-400.64K$928.1K-$-3.54M-$-1.44M-$-586.91K
Operating cash flow$42M$38.1M-$-18.39M-$-25.24M-$-19.29M
Capital expenditure-$-5.91M-$-6.48M-$-9.24M-$-24.33M-$-20.26M
Free cash flow$36.1M$31.6M-$-27.63M-$-49.57M-$-39.55M
Total assets$413.2M$491.1M$466.8M$543M$566.6M
Total debt$26.2M$28.4M$34.2M$39M$21.4M
Net debt-$-39.23M-$-86.32M-$-47.98M-$-50.92M-$-327.13M
Total equity$303.1M$378.4M$261.3M$430.9M$465.9M
Cash and short-term investments$177.2M$260.7M$235.4M$293.1M$348.5M
Income statement
20252024202320222021
Revenue$379.8M$333.8M$280.3M$321.8M$296.4M
Cost of revenue$123.2M$109.6M$102M$112.2M$97.4M
Gross profit$256.6M$224.2M$178.3M$209.6M$199M
Research and development expenses$71.4M$72.4M$81.9M$90.4M$76.5M
Selling, general and administrative expenses$210.2M$205.5M$201.2M$196.4M$152.2M
Other expenses$0.00-$-94.52M$98.6M$0.00$0.00
Operating expenses$281.6M$183.4M$381.7M$286.8M$228.7M
Cost and expenses$404.9M$293M$483.7M$399M$326.1M
Interest income$9.17M$11.8M$11.9M$3.76M$160K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$20.4M$19.8M$19.8M$16M$11.9M
Ebitda-$-4.66M-$-33.99M-$-84.92M-$-60.23M-$-20.2M
Operating income-$-25.07M$40.8M-$-203.36M-$-77.23M-$-29.73M
Total other income/expenses, net$3.99M$12.1M$13.2M$1M-$-2.36M
Income before tax-$-21.08M$52.9M-$-190.14M-$-76.23M-$-32.09M
Income tax expense$270K$310K$140K$380K-$-1.43M
Net income-$-21.35M$52.6M-$-190.28M-$-76.61M-$-30.66M
Weighted average shares outstanding$53.3M$52.8M$53.8M$53.3M$52.2M
Weighted average diluted shares outstanding$53.3M$56.6M$53.8M$53.3M$52.2M
Balance sheet
20252024202320222021
Cash and short-term investments$177.2M$260.7M$235.4M$293.1M$348.5M
Net receivables$42.6M$64.6M$51.1M$66.3M$59.8M
Inventory$26.7M$19.5M$19.5M$19.2M$17.2M
Total current assets$257.1M$351.8M$313.7M$387.9M$433.4M
Property, plant and equipment, net$55.7M$57.9M$65.1M$70.2M$40M
Goodwill and intangible assets$72.3M$78.5M$86M$80.6M$87.2M
Long-term investments$24.2M$0.00$0.00$0.00$0.00
Total non-current assets$156.1M$139.2M$153.1M$155.1M$133.3M
Total assets$413.2M$491.1M$466.8M$543M$566.6M
Accounts payable$9.99M$7.69M$12.9M$9.94M$13.3M
Short-term debt$6.51M$6.1M$5.94M$5.59M$3.96M
Deferred revenue$4.65M$4.85M$4.75M$5.34M$4.21M
Total current liabilities$89.9M$89.4M$78.1M$76M$77.3M
Long-term debt$19.7M$22.3M$28.3M$33.4M$17.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$20.3M$23.3M$127.4M$36.1M$23.4M
Capital lease obligations$26.2M$28.4M$34.2M$39M$21.4M
Total liabilities$110.1M$112.6M$205.5M$112.1M$100.8M
Common stock$50K$50K$50K$50K$50K
Retained earnings-$-735.36M-$-626.24M-$-678.27M-$-460.44M-$-383.19M
Accumulated other comprehensive income (loss)-$-5.51M-$-8.57M-$-6.96M-$-7.5M-$-4.67M
Total equity$303.1M$378.4M$261.3M$430.9M$465.9M
Total investments$135.9M$146M$153.2M$203.2M$0.00
Total debt$26.2M$28.4M$34.2M$39M$21.4M
Net debt-$-39.23M-$-86.32M-$-47.98M-$-50.92M-$-327.13M
Cash flow statement
20252024202320222021
Net income-$-21.35M$52.6M-$-190.28M-$-76.61M-$-30.66M
Depreciation and amortization$20.4M$19.8M$19.8M$16M$11.9M
Stock-based compensation$34.9M$66.4M$49.1M$46.6M$36.1M
Change in working capital$3.81M-$-102.31M$106M-$-14.22M-$-40.97M
Accounts receivable$22.5M-$-13.74M$16M-$-6.66M-$-24.42M
Inventory-$-4.96M-$-1.02M$50K-$-2.86M-$-6.93M
Accounts payable$810K-$-5.11M$2.9M-$-2.05M$1.79M
Net cash provided by operating activities$42M$38.1M-$-18.39M-$-25.24M-$-19.29M
Investments in property, plant and equipment-$-6.59M-$-6.48M-$-9.24M-$-24.33M-$-20.26M
Acquisitions, net$0.00$0.00-$-6.68M-$-610K-$-15.43M
Net cash used for investing activities$2.16M-$-480K$40.5M-$-228.5M$47.7M
Common stock issued$8M$0.00$0.00$0.00$188.9M
Common stock repurchased-$-87.77M-$-520K-$-27.54M-$-640K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-93.39M-$-5.61M-$-29.61M-$-4.54M$185.6M
Net change in cash-$-49.29M$32.5M-$-7.66M-$-258.25M$213.8M
Cash at end of period$66M$115.3M$82.8M$90.4M$348.7M
Operating cash flow$42M$38.1M-$-18.39M-$-25.24M-$-19.29M
Capital expenditure-$-5.91M-$-6.48M-$-9.24M-$-24.33M-$-20.26M
Free cash flow$36.1M$31.6M-$-27.63M-$-49.57M-$-39.55M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About CareDx, Inc

        CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

        CEO
        John Walter Hanna Jr.
        Employees
        765
        Beta
        2.43

        Explore

        Frequently asked questions

        What is the intrinsic value of CareDx, Inc (CDNA)?

        CareDx, Inc (CDNA) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CDNA undervalued?

        CDNA trades at a price of $70.00 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.